Clinical trials: B-cell Malignancy, Low-grade
Leukaemia, Lymphocytic, Chronic
Ofatumumab Cardiac Repolarization (QTc) Study in Fludarabine-Refractory Chronic Lymphocytic Leukemia Subjects
Ofatumumab is a fully-human monoclonal antibody that exhibits high binding affinity to an antigen on the surface of B lymphocytes.
- Trial name
- NCT01110031
- Testing
- Ofatumumab
- Where
- 4 sites in United States, Australia and 1 more
- Volunteers
- 12 people
- Sponsor
- GlaxoSmithKline
Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell
A Study of JNJ-64264681 in Participants With Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia
The purpose of the study is to determine the recommended Phase 2 dose(s) (RP2D[s]) in B cell non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL) in Part 1 and to evaluate the safety of JNJ-64264681 at the RP2D(s) in…
- Trial name
- NCT04210219
- Testing
- JNJ-64264681
- Where
- 15 sites in United States, Georgia and 5 more
- Volunteers
- 85 people
- Sponsor
- Janssen Research & Development, LLC
Chronic Lymphocytic Leukemia, Peripheral T-cell Lymphoma
Phase 1b Safety and Efficacy Study of TRU-016
The purpose of this study is to evaluate the efficacy and safety of TRU-016 in combination with rituximab, in combination with obinutuzumab, in combination with rituximab and idelalisib, or in combination with ibrutinib in…
- Trial name
- NCT01644253
- Testing
- 20 mg/kg TRU-016 + Rituximab, 10 mg/kg TRU-016 + Rituximab, TRU-016 20 mg/kg + Obinutuzumab
- Where
- 8 sites in United States
- Volunteers
- 87 people
- Sponsor
- Aptevo Therapeutics
Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL)
A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies
This is a first-in-human Phase 1a/1b multicenter, open-label oncology study designed to evaluate the safety and anti-cancer activity of NX-2127 in patients with advanced B-cell malignancies.
- Conditions
- Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL), Waldenstrom Macroglobulinemia (WM), Mantle Cell Lymphoma (MCL)
- Trial name
- NCT04830137
- Testing
- NX-2127
- Where
- 16 sites in United States
- Volunteers
- 248 people
- Sponsor
- Nurix Therapeutics, Inc.
Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia
Safety, Tolerability Study of SG2000 in the Treatment of Advanced Chronic Lymphocytic Leukemia and Acute Myeloid Leukemia
The purpose of this study is to determine if the experimental drug, SG2000 is safe and tolerable in the treatment of participants with advanced chronic lymphocytic leukemia and acute myeloid leukemia whose standard treatment did…
- Trial name
- NCT02034227
- Testing
- SG2000
- Where
- 2 sites in United States
- Volunteers
- 6 people
- Sponsor
- Spirogen
Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia
Study to Investigate the Safety and Tolerability of Odronextamab in Patients With CD20+ B-Cell Malignancies
This study has two parts with distinct study objectives and study design. In part A, odronextamab is studied as an intravenous (IV) administration with a dose escalation and a dose expansion phase for B-NHL and CLL.
- Trial name
- ELM-1 (NCT02290951)
- Testing
- Odronextamab multiple dose levels
- Where
- 22 sites in United States, France and 3 more
- Volunteers
- 200 people
- Sponsor
- Regeneron Pharmaceuticals
Leukemia, Lymphoblastic, Acute, T-cell, Myelogenous Leukemia
A Notch Signalling Pathway Inhibitor for Patients With T-cell Acute Lymphoblastic Leukemia/Lymphoma (ALL)(0752-013)
A Notch signalling pathway inhibitor study in pediatric and adult patients with relapsed (worsening) or refractory (not responding to treatment) T-cell acute lymphoblastic leukemia/lymphoma (T-ALL).
- Conditions
- Leukemia, Lymphoblastic, Acute, T-cell, Myelogenous Leukemia, Chronic Lymphocytic Leukemia, Myelodysplastic Syndromes
- Trial name
- NCT00100152
- Testing
- MK0752, (Notch Inhibitor)
- Volunteers
- 50 people
- Sponsor
- Merck Sharp & Dohme LLC
B-cell Non-Hodgkins Lymphoma, Chronic Lymphocytic Leukemia
Study to Evaluate Safety and Tolerability of XmAb13676 (Plamotamab) in Patients With CD20-expressing Hematologic Malignancies
The purpose of this study is to determine the safety and tolerability of intravenous (IV) and subcutaneous (SC) administration of XmAb13676 and to determine the maximally tolerated dose (MTD) and/or recommended dose (RD).
- Trial name
- NCT02924402
- Testing
- XmAb13676
- Where
- 23 sites in United States, France and 2 more
- Volunteers
- 154 people
- Sponsor
- Xencor, Inc.
Leukaemia, Lymphocytic, Chronic
A Phase I/II, Open-label Study of Ofatumumab Added to Chlorambucil in Previously Untreated Japanese Patients With Chronic Lymphocytic Leukemia
This is an open-label study to evaluate tolerability, safety, efficacy and pharmacokinetic profile of ofatumumab in combination with chlorambucil in Japanese patients with previously untreated Chronic Lymphocytic Leukemia (CLL).
- Trial name
- NCT01563055
- Testing
- chlorambucil, tablets, ofatumumab (GSK1841157) infusion
- Where
- 6 sites in Japan
- Volunteers
- 10 people
- Sponsor
- GlaxoSmithKline
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
A Study of Dinaciclib in Combination With Rituximab in Participants With Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (P07974)
The purpose of this study is to determine the maximum-tolerated dose (MTD) of dinaciclib therapy in combination with rituximab in chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL).
- Trial name
- NCT01650727
- Testing
- Dinaciclib, Rituximab
- Volunteers
- 5 people
- Sponsor
- Merck Sharp & Dohme LLC
Lymphoma, Hodgkin Disease
Study of the Safety and Tolerability of PCI-24781 in Patients With Lymphoma
The first part of the study will determine the highest dose of study drug that can be taken without causing serious side effects in patients with lymphoma.
- Conditions
- Lymphoma, Hodgkin Disease, Lymphoma, Non-Hodgkin
- Trial name
- PCYC-0403 (NCT00724984)
- Testing
- PCI-24781
- Where
- 8 sites in United States
- Volunteers
- 55 people
- Sponsor
- Pharmacyclics LLC.
Chronic Lymphocytic Leukemia
Efficacy and Safety of Idelalisib in Combination With Obinutuzumab Compared to Chlorambucil in Combination With Obinutuzumab for Previously Untreated Chronic Lymphocytic Leukemia
The primary objective of this study is to evaluate the effects of idelalisib with obinutuzumab versus the combination of chlorambucil and obinutuzumab on progression-free survival (PFS) in participants with previously untreated…
- Trial name
- NCT01980875
- Testing
- Idelalisib, Chlorambucil, Obinutuzumab
- Where
- 18 sites in United States, Australia and 6 more
- Volunteers
- 57 people
- Sponsor
- Gilead Sciences
Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL)
A Study of Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Treated With Lisocabtagene Maraleucel in the Post-Marketing Setting
The purpose of this study is to characterize the long-term safety of lisocabtagene maraleucel (liso-cel), focusing on patients treated in the chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) indication, and…
- Trial name
- NCT06788639
- Testing
- Lisocabtagene maraleucel
- Where
- United States
- Volunteers
- 300 people
- Sponsor
- Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Chronic Lymphocytic Leukemia and Relapsed and Refractory Mantle Cell Lymphoma
Acalabrutinib Study in Indian Patients With Chronic Lymphocytic Leukaemia & Relapsed and Refractory Mantle Cell Lymphoma
This study is plan to assess the safety and efficacy of Acalabrutinib in Indian patients with chronic lymphocytic leukaemia (CLL) and relapsed and refractory mantle cell lymphoma (MCL)
- Trial name
- NCT04930536
- Testing
- Acalabrutinib capsule
- Where
- 15 sites in India
- Volunteers
- 103 people
- Sponsor
- AstraZeneca
B-cell Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Safety of PCI-32765 in Chronic Lymphocytic Leukemia
The purpose of this study is to establish the safety and efficacy of orally administered PCI-32765 in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma.
- Trial name
- NCT01105247
- Testing
- PCI-32765
- Where
- 10 sites in United States
- Volunteers
- 133 people
- Sponsor
- Pharmacyclics LLC.
Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab and a Combined Regimen of Mosunetuzumab and Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia
This study will assess the safety, tolerability, pharmaokinetics, and preliminary efficacy of mosunetuzumab (Lunsumio) monotherapy in participants with relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL) or small…
- Trial name
- NCT05091424
- Testing
- Mosunetuzumab, Tocilizumab, Venetoclax
- Where
- 31 sites in United States, Australia and 8 more
- Volunteers
- 332 people
- Sponsor
- Hoffmann-La Roche
Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
A Study of Lacutoclax (LP-108) in Patients With Relapsed/Refractory CLL/SLL
The goal of this clinical trial is to evaluate the efficacy and safety of Lacutoclax, an oral selective BCL-2 inhibitor, in patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL).
- Trial name
- NCT07609823
- Testing
- Lacutoclax
- Where
- China
- Volunteers
- 75 people
- Sponsor
- Guangzhou Lupeng Pharmaceutical Company LTD.
Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL)
A Study of ME-401 in Subjects With CLL/SLL, FL, and B-cell Non Hodgkin's Lymphoma
A Three-Arm Study of ME-401 in Subjects with Relapsed/Refractory CLL/SLL or FL, of ME-401 in Combination with Rituximab in Subjects with Relapsed/Refractory CLL/SLL or B-cell NHL, and of ME-401 in Combination with Zanubrutinib in…
- Conditions
- Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL), Follicular Lymphoma (FL), Marginal Zone B Cell Lymphoma
- Trial name
- NCT02914938
- Testing
- ME-401, Rituximab, Zanubrutinib
- Where
- 24 sites in United States, Switzerland
- Volunteers
- 97 people
- Sponsor
- MEI Pharma, Inc.
Relapsed or Refractory B-cell Lymphoma, Diffuse Large B-cell Lymphoma (DLBCL)
A Study of MS-553 in Patients With Relapsed or Refractory B-cell Lymphoma
This is a Phase I/II, single-arm, multicenter, open-label study which is divided into two portions: Phase I is dose escalation portion, in which subjects with relapsed or refractory B-cell lymphoma will be enrolled except…
- Conditions
- Relapsed or Refractory B-cell Lymphoma, Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma (FL), Mantle Cell Lymphoma (MCL)
- Trial name
- NCT05720052
- Testing
- MS-553
- Where
- China
- Volunteers
- 8 people
- Sponsor
- MingSight Pharmaceuticals, Inc
Chronic Lymphocytic Leukemia
A Study to Assess Change in Patient Experience in Adult Participants With Chronic Lymphocytic Leukemia (CLL) Receiving Oral Venetoclax Tablets + Intravenous Rituximab or Bruton's Tyrosine Kinase Inhibitors Tablets in the United Kingdom
Chronic lymphocytic leukemia (CLL), a form of Non-Hodgkin's Lymphoma, is the most common type of leukemia in adults, affecting approximately 3,800 people in the UK each year.
- Trial name
- ELECTRIC (NCT05555979)
- Where
- 10 sites in United Kingdom
- Volunteers
- 56 people
- Sponsor
- AbbVie